Healthcare
Tilray Brands, Inc. (TLRY)
Data as of July 8, 2026
Environment story
The 10-K contains no disclosed Scope 1/2/3 emissions data, no renewable-electricity percentage, and no net-zero target year, triggering default deductions for undisclosed Scope 3 trajectory and absent net-zero credibility. No specific, sourced environmental controversy (e.g., toxic waste or water-use fines) is documented in the filing, so no severity deduction was applied there. The filing does reference agricultural/crop risk (climate, disease, water) and GMP-certified facilities (Portugal, Germany) but does not quantify any physical decarbonization capital investment, so no addition was warranted. This is a disclosure-gap-driven score, not a claim of poor environmental performance.
Criticisms on file
-
Risk factor disclosure acknowledges general exposure to environmental, health and safety law violations (waste disposal, emissions, water/land use) with potential for fines, clean-up costs, or suspension of operations, though no specific enforcement action is detailed.Source: TLRY_10k.txt, Item 1A Risk Factors - 'Failure to comply with safety, health and environmental regulations...'
Disclosed initiatives
-
EU-GMP Certified Cultivation FacilitiesTilray Portugal and Aphria RX (Germany) hold EU-GMP certification for cultivation and production, subject to ongoing compliance audits.
Social story
The filing discloses no CEO-to-median-worker pay ratio, no leadership diversity statistics, and no supply-chain human-rights audit results, so no rubric deductions were applied for these categories absent verifiable data. The company explicitly states it has not experienced strikes; a Portland, Oregon facility operates under a ratified three-year collective bargaining agreement covering ~50 employees, and Portugal employees are covered by a government-mandated (not workforce-initiated) collective agreement. No NLRB complaints, union-suppression activity, or strikes within the last 24 months are disclosed.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
No disclosed initiatives on file for this pillar.
Governance story
No dual-class share structure is disclosed (single class of common stock), so no deduction was applied there. Board independence percentage and lobbying expenditure figures are not disclosed in this filing, so no rubric deduction was assessed for those items absent verifiable data. However, the company discloses ongoing securities class-action litigation (originating from predecessor Aphria) plus a broad set of pending/threatened legal proceedings covering product liability, unfair trade practices, antitrust, and other matters, which is treated as an active regulatory/legal proceeding risk warranting a governance deduction. The company also disclosed a Nasdaq minimum-bid-price non-compliance notice and a pending reverse stock split, reflecting elevated governance/listing risk, though this is not itself a fine or antitrust action.
Criticisms on file
-
Tilray (via predecessor Aphria) has been named defendant in multiple U.S. securities class-action lawsuits that remain ongoing, alongside other pending/threatened litigation across multiple jurisdictions.Source: TLRY_10k.txt, Item 1A Risk Factors - 'Risks Related to Ongoing Litigation Claims'
-
Received Nasdaq non-compliance notice (March 25, 2025) for failing to maintain the $1.00 minimum bid price requirement under Listing Rule 5450(a)(1); board and stockholders approved a reverse stock split to regain compliance.Source: TLRY_10k.txt, Item 1A Risk Factors - 'Our failure to meet the continued listing requirements of Nasdaq...'
Disclosed initiatives
No disclosed initiatives on file for this pillar.
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Tilray Brands, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Tilray Brands, Inc. in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics